June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Tissue transglutaminase mediated ocular hypertension and effects of a small molecule crosslinking modulator
Author Affiliations & Notes
  • Urmimala Raychaudhuri
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • J Cameron Millar
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Abbot F Clark
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Urmimala Raychaudhuri, None; J Cameron Millar, None; Abbot Clark, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3494. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Urmimala Raychaudhuri, J Cameron Millar, Abbot F Clark; Tissue transglutaminase mediated ocular hypertension and effects of a small molecule crosslinking modulator. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3494.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Transforming Growth Factor-β2 (TGF-β2) induces expression of the crosslinking enzyme tissue transglutaminase (TGM2) in human trabecular meshwork (TM) cells. We studied (1) whether TGM2 overexpression in the TM can increase intraocular pressure (IOP) and decrease aqueous humor (AH) outflow facility (C) in mice and (2) whether a small molecule TGM2 inhibitor can decrease ECM crosslinking in-vitro.

Methods : 2μl of the expression vector Ad5.CMV.TGM2 (1-50 × 106 pfu) was injected intravitreally (OS) in BALBc/J (n=18) or C57BL/6J mice (n=9) while contralateral eyes served as uninjected controls. Daytime conscious IOPs were measured (Tonolab) twice/week. C was measured following IOP elevation in BALBc/J (n=6) and C57BL/6J (n=3) mice. In vitro, primary human glaucoma TM cells (GTM 125, GTM 60 A and GTM 46) were treated with a small molecule TGM2 inhibitor (5nM).

Results : Ad5.CMV.TGM2 injection significantly elevated IOP, where BALBc/J showed maximum IOP at Day 19, [15.86 mmHg (injected) vs. 10.7 mmHg (control), (p<0.0001, ANOVA)] and C57BL/6J showed maximum IOP at Day 17 [(17.09 mmHg (injected) vs. 12.01 mmHg (control), (p<0.05), ANOVA]. In BALBc/J, C in transduced eyes (0.013 μl/min/mmHg) was significantly lower than uninjected eyes (0.021 μL/min/mmHg), p = 0.01, paired Student’s t-test. In C57BL/6J, C in injected eyes (0.012 μl/min/mmHg) was significantly lower than uninjected eyes (0.019 μL/min/mmHg), p = 0.046, paired Student’s t-test. In GTM cells, primary GTM cells showed high endogenous ECM crosslinking, and treatment with a TGM2 inhibitor (5nM) reduced fibronectin expression and crosslinking but did not affect TGM2 expression as seen with immunocytochemistry and western immunoblotting.

Conclusions : TGM2 overexpression in the mouse TM significantly elevates IOP and decreases the AH outflow facility. A TGM2 inhibitor decreased crosslinking in TM primary cells. In future, we will study the role of TGM2 and the TGM2 small molecule inhibitor in TGFβ2 induced ocular hypertension.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×